Clinical & Scientific

Sensorium Therapeutics advances SNTX-2643, a novel anxiety drug, while adding a new CMO and an expert advisory board to guide its clinical journey.

EOM Pharmaceutical gets FDA clearance for a trial on EOM613, a potential first-in-class treatment for cancer cachexia, a severe wasting syndrome.

With late-stage trials for its revolutionary eye and lung disease treatments, 4DMT must convince investors its focused, high-stakes strategy will pay off.

A new partnership between TD2 Oncology and Panome Bio aims to merge clinical expertise with deep multi-omics data to accelerate personalized cancer therapies.

A biotech firm's novel marine compound, now patented, shows promise in modulating key cell pathways, offering a new strategy against intractable diseases.

A Seattle biotech's award-winning vaccine for a deadly fever is now in human trials, powered by innovative tech that could change global vaccine deployment.

A potential first-in-class antibody-drug conjugate for colorectal cancer begins a pivotal trial, aiming to help patients who have run out of options.

With a key hire from lithium giant Albemarle and a new IR head, Power Metals signals a major push to develop its world-class Case Lake cesium project.

With a new CCO and advanced T-Body™ platform, Invenra is shifting from R&D to aggressive commercialization. Can it dominate the multispecific antibody market?

A new collaboration between the digital health giant and a top cancer center aims to deliver expert insights to doctors worldwide, tackling a complex field.

A first-in-class drug for anxiety has entered patient trials, offering a novel approach that could reshape mental healthcare for millions.

Led by OrbiMed, the financing will propel Accro's promising oral RIPK2 inhibitor for Ulcerative Colitis into a pivotal Phase IIb clinical trial.

Neurovascular giant Balt deepens its Irvine roots with a new facility, a $400M investment, and plans for 700 jobs to accelerate stroke-fighting tech.

Alaunos Therapeutics reports positive preclinical data for its oral metabolic drug, but with a perilous financial runway, the race for survival is on.

The biotech firm raises cash via a complex warrant deal, diluting shares to fund its promising but challenging RNAi therapy for deadly KRAS-driven cancers.

A new six-month semaglutide implant is entering clinical trials, aiming to solve the adherence crisis plaguing GLP-1 drugs like Ozempic and Wegovy.

With a novel drug for schizophrenia and deep financial backing, LB Pharmaceuticals is advancing a promising new therapy for complex mental illnesses.

The cell-engineering firm posted a smaller-than-expected loss and announced a share buyback, signaling confidence despite a dip in core Q1 revenue.

From nano-surfactants to pharmaceuticals, SureNano Science is betting its future on a novel obesity drug. Can this microcap survive the big leagues?

With its new CCO, the AI health-tech firm aims to commercialize its patient-data platform, tackling billion-dollar delays in drug development.